Understanding resistance in HER2-positive breast cancer treatments
MULTIPLEXED ISOFORM QUANTIFICATION IN HER2-POSITIVE BREAST CANCER
This study is looking into why some patients with HER2-positive breast cancer don't respond well to certain treatments, focusing on different forms of the HER2 protein that might be causing issues, with the goal of finding better ways to help those who have had their cancer come back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-10778574 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind resistance to targeted therapies in patients with HER2-positive breast cancer. It focuses on the molecular heterogeneity of the HER2 protein, particularly the presence of truncated isoforms that may contribute to treatment failure. By developing methods to quantify these isoforms at the cellular level, the research aims to provide insights that could lead to more effective treatment strategies for patients experiencing recurrence. The approach involves advanced techniques to analyze the different forms of HER2 proteins in cancer cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2-positive breast cancer who have experienced recurrence after initial treatment.
Not a fit: Patients with HER2-negative breast cancer or those who have not undergone targeted therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with HER2-positive breast cancer, potentially reducing recurrence rates.
How similar studies have performed: Previous research has shown promise in understanding molecular heterogeneity in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Berkeley, United States
- University of California Berkeley — Berkeley, United States (Active)
Researchers
- Principal investigator: Herr, Amy Elizabeth — University of California Berkeley
- Study coordinator: Herr, Amy Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.